Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Acquires Small San Diego Drug Discovery Firm Maxia Pharmaceuticals

NEW YORK, Nov. 12-Incyte Genomics plans to acquire Maxia Pharmaceuticals, a small San Diego-based drug discovery company, the firm said today.


Maxia, which has only 28 employees, is developing small molecule treatments for chronic diseases like diabetes, hyperlipidemia, and cancer, and has several lead compounds in preclinical development. Incyte is particularly interested in its success with small molecule inhibitors of protein phosphatases, said Incyte CEO Robert Stein in a statement.


Incyte will acquire the company for up to $28.3 million in cash and stock, plus up to $14 million in future milestone payments. Maxia will then become a subsidiary of Incyte. The boards of directors of both companies have approved the agreement, and it will be completed pending shareholder approval.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.